Company: INKT
Filing Date: 2025-12-10
Form Type: S-3/A
Source: 0001193125-25-314252
Chunk: 13

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-12-10
Form: S-3/A
Chunk 13
---
 will receive 
 from the sale;                                                                                                  |

| • |     | if any of the securities being registered are to be offered otherwise than for cash, the general purposes of the                                                      
 distribution, the basis upon which the securities are to be offered, the amount of compensation and other expenses of distribution, and by whom they are to be borne; |

| • |     | any delayed delivery arrangements; |

| • |     | any over-allotment or other options under which underwriters may purchase additional securities from us; |

| • |     | any agency fees or underwriting discounts and other items constituting agents’ or underwriters’ 
 compensation;                                                                                   |

| • |     | any public offering price; |

| • |     | any discounts, commissions or concessions allowed or reallowed or paid to dealers; |

| • |     | the identity and relationships of any finders, if applicable; and |

9

| • |     | any securities exchange or market on which the securities may be listed. |

Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Unless otherwise indicated in the prospectus supplement, subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, dealer or agent, the nature of any such relationship. We may use a remarketing firm to offer the securities in connection with a remarketing arrangement upon their purchase. Remarketing firms would act as principals for their own account or as agents for us. These remarketing firms would offer or sell the securities pursuant to the terms of the securities. A prospectus supplement will identify any remarketing firm and